Vadanem, Mitsubishi Tanabe Pharma’s new tablet anemia drug, will likely receive approval from the U.S. Food and Drug Administration by early April and make a second attempt at getting a reimbursement listing in Korea.

If the company gets the drug reasonably priced comparable to a weighted average price of the substitute during drug pricing negotiation with the Health Insurance Review and Assessment Service (HIRA), the drug will be recorded as the first new anemia drug in tablet form to be commercialized in Korea.

According to the pharmaceutical industry, Vadanem (vadadustat) has been re-submitted for U.S. approval for the indication of ‘Treating anemia in adult patients with ch